Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: Synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N′-{4-(4-quinolyloxy)phenyl}ureas

Journal of Medicinal Chemistry

Volumn 48, Issue 5, 2005, Pages 1359-1366

  Kubo, Kazuo ^a   Shimizu, Toshiyuki ^a   Ohyama, Shin Ichi ^a   Murooka, Hideko ^a   Iwai, Akemi ^a   Nakamura, Kazuhide ^a   Hasegawa, Kazumasa ^a   Kobayashi, Yoshiko ^a   Takahashi, Noriko ^a   Takahashi, Kazumi ^a   Kato, Shinichiro ^a   Izawa, Toshio ^a   Isoe, Toshiyuki ^a  

^a KIRIN BREWERY CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; INSULIN RECEPTOR; KI 8751; N PHENYL N' [4 (4 QUINOLYLOXY)PHENYL]UREA DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GLIOMA; HUMAN; HUMAN CELL; IC 50; LUNG CARCINOMA; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; STOMACH CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, NUDE; PHENYLUREA COMPOUNDS; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20144375600     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030427r     Document Type: Article

References (34)

1. Folkman, J. Anti-Angiogenesis: New Concept for Therapy of Solid Tumors. Ann. Surg. 1972, 175, 409-416.
2. Liotta, L. A.; Kleinerman, J.; Saidel, G. M. Quantitative Relationships of Intravascular Tumor Cells, Tumor Vessels, and Pulmonary Metastases following Tumor Implantation. Cancer Res. 1974, 34, 997-1004.
3. Eckhardt, S. G: Angiogenesis Inhibitors as Cancer Therapy. Hosp. Pract. 1999, 63-84.
4. Bergers, G.; Javaherian, K.; Lo, K.-M.; Folkman, J.; Hanahan, D. Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice. Science 1999, 284, 808-812.
5. Fan, T.-P. D.; Jaggar, R.; Bicknell, R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci. 1995, 16, 57-66.
6. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
7. Kolch, W.; Martiny-Baron, G.; Kieser, A.; Marme, D. Regulation of the expression of VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res. Treat. 1995, 36, 139-155.
8. Leenders, W. P. J. Targetting VEGF in anti-angiogenic and antitumour therapy: Where are we now? Int. J. Exp. Pathol. 1998, 79, 339-346.
9. Strawn, L. M.; McMahon, G.; App, H.; Schreck, R.; Kuchler, W. R.; Longhi, M. P.; Hui, T. H.; Tang, C.; Levitzki, A.; Gazit, A.; Chen, I.; Keri, G.; Orfi, L.; Risau, W.; Flamme, I.; Ullrich, A.; Hirth, K. P.; Shawver, L. K. Flk-1 as a Target for Tumor Growth Inhibition. Cancer Res. 1996, 56, 3540-3545.
10. Millauer, B.; Longhi, M. P.; Plate, K. H.; Shawver, L. K.; Risau, W.; Ullrich, A.; Strawn, L. M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res., 1996, 56, 1615-1620.
11. Kim, K. J.; Li, B.; Winer, J.; et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362, 841-844.
12. Prewett, M.; Huber, J.; Li, Y.; et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999, 59, 5209-5218.
13. Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997-2000. Exp. Opin. Ther. Pat. 2001, 11, 405-429.
14. Connell, R. D.; Beebe, J. S. Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000-September 2000. Exp. Opin. Ther. Pat. 2001, 11, 77-114.
15. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors that Exhibit Selectivity toward Particular Receptor Tyrosine Kinases. J. Med. Chem. 1998, 41, 2588-2603.
16. Fong, T. A. T.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types. Cancer Res. 1999, 59, 99-106.
17. Sun, L.; Tran, N.; Liang, C.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K.; Shawver, L. K.; McMahon, G.; Tang, C. Design, synthesis and evaluation of substituted 3-[(3- or 4-carboxy-ethylpyrrol-2-y1)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem. 1999, 42, 5120-5130.
18. Laird, A. D.; Vajkoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, T. A. T.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon, G.; Cherrington, J. M. SU6668 Is a Potent Antiangiogenic and Antitumour Agent That Induces Regression of Established Tumors. Cancer Res. 2000, 60, 4152-4160.
19. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S. E.; Ple, P.; Lohmann, J.-J. M.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Curwen, J. O.; Kendrew, J.; Lambert-van-der-Brempt, C. Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 1999, 42, 5369-5389.
20. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Curwen, J. O.; Hennequin, L. F.; Thomas, A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H.; Wadsworth, P. F. Cancer Res. 2000, 60, 970-975.
21. Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; E.; Ple, P.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure-activity Relationship of a Series of Potent, Orally Active, VEGF Receptor TyrosineKinase Inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
22. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Valentine, P. J.; Curwen, J. O.; Musgrove, H. L.; Graham, G. A.; Hughes, G. D.; Thomas, A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H. P.; Wadsworth, P. F.; Bigley, A. L.; Hennequin, L. F. Cancer Res. 2002, 62, 4645-4655.
23. Bold, G.; Altmann, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Bruggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New Anilinophthalazines as Potent and Orally well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
24. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K.-H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F.; Marme, D. Cancer Res. 2000, 60, 2178-2189.
25. Fernand, N. H.; Hurwitz H. I.; Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin. Oncol. 2003, 3 Suppl 6, 39-50.
26. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, J. D.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. N. Engl. J. Med. 2003, 349, 427-434.
27. Kubo, K.; Shimizu, T.; Ohyama, S.; Murooka, H.; Nishitoba, T.; Kato, S.; Kobayashi, Y.; Yagi, M.; Isoe, T.; Nakamura, K.; Osawa, T.; Izawa, T. A Novel Series of 4-Phenoxyquinolines: Potent and Highly Selective Inhibitors of PDGF Receptor Autophospholylation. Bioorg. Med. Chem. Lett. 1997, 23, 22935-2940.
28. Yagi, M.; Kato, S.; Kobayashi, Y.; Kubo, K.; Ohyama, S.; Shimizu, T.; Nishitoba, T.; Isoe, T.; Nakamura, K.; Ohashi, H.; Kobayashi, N.; Iinuma, N.; Osawa, T.; Onose, R.; Osada, H. Selective Inhibition of Platelet-Derived Growth Factor (PDGF) Receptor Autophosphorylation and PDGF-Mediated Cellular Events by Quinoline Derivatives. Exp. Cell Res. 1997, 234, 285-292.
29. Yagi, M.; Kato, S.; Kobayashi, Y.; Kobayashi, N.; Iinuma, N.; Nakamura, K.; Kubo, K.; Ohyama, S.; Murooka, H.; Shimizu, T.; Nishitoba, T.; Osawa, T.; Nagano, N. Beneficial Effects of a Novel Inhibition of Platelet-Derived Growth Factor Receptor Autophosphorylation in the Rat with Mesangial Proliferative Glomerulonephritis. Gen. Pharmacol. 1998, 31, 765-773.
30. Kubo, K.; Ohyama, S.; Shimizu, T.; Takami, A.; Murooka, H.; Nishitoba, T.; Kato, S.; Yagi, M.; Kobayashi, Y.; Iinuma, N.; Isoe, T.; Nakamura, K.; Iijima, H.; Osawa, T.; Izawa. T. Synthesis and Structure-Activity Relationship for New Series of 4-Phenoxyquinoline Derivatives as Specific Inhibitors of Platelet-Derived Growth Factor Receptor Tyrosine Kinase. Bioorg. Med. Chem. 2003, 11, 5117-5133.
31. Price, C. C.; Roberts, R. M. The synthesis of 4-hydroxyquinolines. I. Through ethoxymethylenemalonic ester. J. Am. Chem. Soc. 1946, 68, 1204-1208.
32. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Shoalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 267-276.
33. Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Rubin, J. R.; Denny, W. A. Tyrosine Kinase Inhibitors. 12. Synthesis and Structure-Activity Relationships for 6-Substituted 4-(Phenylamino)pyrim-ido[5,4-d]pyrimidines Designed as Inhibitors of Epidermal Growth Factor Receptor. J. Med. Chem. 1997, 40, 1820-1826.
34. Sawano, A.; Takahashi, T.; Yamaguchi, S.; Aonuma, M.; Shibuya, M.Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ. 1996, 7, 213-21.